Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson JN, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K.
Al-Sawaf O, et al. Among authors: hallek m.
Nat Commun. 2023 Oct 23;14(1):6724. doi: 10.1038/s41467-023-42562-2.
Nat Commun. 2023.
PMID: 37872229
Free PMC article.
No abstract available.